GSK · Pharma and healthcare · one day
GSK (GSK): news on Wednesday 28 October 2026
News from the 24 hours to Wednesday morning, 28 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage centred on GSK's intention to raise the number of its cancer drugs in trials to nearly twice the current level next year, along with upbeat late-stage results for the osteosarcoma treatment it developed with Hansoh. Ahead of the upcoming quarterly results, previews were mostly stable, although a few flagged concern about US pricing and tariffs.
What drove it
- oncology pipeline expansion
- Ris-Rez trial data
- Q3 results preview
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Thu 22 Oct | +10.0 | 37 |
| Fri 23 Oct | +7.2 | 18 |
| Sat 24 Oct | +8.0 | 15 |
| Sun 25 Oct | +2.0 | 6 |
| Mon 26 Oct | +5.7 | 5 |
| Tue 27 Oct | +9.3 | 29 |
| Wed 28 Oct | +7.0 | 23 |
8 stories · 23 headlines · strongest first
Pharma and healthcare on 28 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK forecasts almost twice as many cancer drugs in trials in 2027 +8.37 headlines today · WSJ and others report GSK expects its clinical cancer pipeline to nearly double next year after dealmaking. | ||
| +9.2 | Company expects far larger number of cancer programmes in trials. | |
| +9.2 | Acquisitions and licensing set to nearly double cancer pipeline. | |
| +8.3 | Company anticipates a much bigger cancer development portfolio. | |
| +8.3 | Dealmaking expected to expand cancer trial pipeline significantly. | |
| +8.3 | Newspaper report of planned doubling of cancer trials. | |
| +7.5 | Strategic emphasis on expanding cancer business. | |
| +7.5 | Report says re-entry into cancer treatment is yielding results. | |
| GSK third-quarter results due 28 October +1.54 headlines today · 8 in all, since 24 October · Previews look ahead to GSK's third-quarter results and analyst expectations. | ||
| +3.3 | Analysts expect a solid quarter with cost savings in focus. | |
| +2.5 | Analysts expect modest revenue growth before quarterly update. | |
| −1.7 | Concerns over US drug pricing and tariffs ahead of results. | |
| 0.0 | Factual note on results date and share price. | |
| GSK and Hansoh bone cancer drug slows disease progression in China trial +9.73 headlines today · 8 in all, since 27 October · Reports state that, in a phase 3 trial in China, the Ris-Rez ADC lowered the risk of disease progression or death by 67% in relapsed osteosarcoma. | ||
| +9.2 | Licensed cancer drug shows large cut in progression risk in trial. | |
| +9.2 | Strong late-stage trial result for partner-developed cancer drug. | |
| +8.3 | Partner reports positive late-stage survival data for licensed cancer drug. | |
| GSK's return to oncology draws press analysis +7.93 headlines today · 6 in all, since 27 October · Commentary looks at GSK's oncology progress and what it means for investors. | ||
| +8.3 | Favourable trial outcomes support the cancer growth story. | |
| +5.8 | Valuation commentary suggests shares trade below estimated worth after data. | |
| +5.8 | Discusses investor implications of progress in cancer development. | |
| GSK presents ovarian cancer results for mo-rez at ESMO +7.02 headlines today · 11 in all, since 25 October · GSK presented pipeline data at the ESMO congress and investor update. | ||
| +8.3 | Investor event highlighted encouraging cancer pipeline data. | |
| +3.3 | Company presenting oncology material at major medical conference. | |
| Brokers rate GSK +1.72 headlines today · 7 in all, since 22 October · Barclays and RBC ratings on GSK are reported. | ||
| +4.2 | Broker price target set above recent trading level. | |
| 0.0 | Broker keeps a middling rating, no change in view. | |
| FDA clears Hibsago, GSK's medicine for chronic hepatitis B +10.01 headline today · 46 in all, since 21 October · A biotech news roundup mentions GSK's hepatitis B approval. | ||
| +5.0 | Regulatory approval for hepatitis B treatment mentioned among sector news. | |
| GSK share price moves and technical views −0.41 headline today · 6 in all, since 24 October · GSK shares are trading sideways near 1,895p. | ||
| +0.8 | Share price moving flat with balanced technical signals. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.